Singapore, Oct. 29 -- PeptiDream Inc., a public biopharmaceutical company based in Kawasaki, Japan, focused on the discovery and development of peptide- based therapeutics and PDRadiopharma Inc., a wholly owned subsidiary of PeptiDream, have announced that its subsidiary, PDRadiopharma, has received formal approval from the Kazusa Akademia Park Research Institute and Related Facilities Promotion Council to move forward with the development of a new manufacturing facility at Kazusa Akademia Park with an investment of Approximately JPY 16.5 billion (breakdown: JPY 11.0 billion for buildings and JPY 5.5 billion for equipment and other costs).

Published by HT Digital Content Services with permission from BioSpectrum Asia....